Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.

ABSTRACT:

Background

The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin. Until recently, evidence for optimal sequencing post second-line was sparse. Trifluridine/tipiracil (indicated for mCRC and gastric cancer after standard chemotherapies) was made available to UK patients via a named patient programme (NPP) before receiving marketing authorisation in Europe in 2016, allowing characterisation of UK treatment pathways, and evaluation of trifluridine/tipiracil in a UK non-trial population.

Methods

Data collected routinely for the NPP were analysed to describe the patient demographics, clinical characteristics and treatment pathways. Patients

SUBMITTER: Iveson T 

PROVIDER: S-EPMC6998075 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature